Condition: Acute Ischemic Stroke · Sponsor: First Affiliated Hospital of Harbin Medical University
This prospective multicenter cohort study aims to evaluate the effectiveness and safety of early PCSK9 inhibitor therapy in patients with large-artery atherosclerotic ischemic stroke. The study will compare early neurological improvement, lipid-lowering effect, 90-day functional outcome, recurrent cardio-cerebrovascular events, and safety outcomes between patients treated with evolocumab plus statin and those treated with statin alone.
This description comes directly from the study's public registry record.
Zhongling Zhang · +8613503615988 · zhang777hyd@163.com
Shanshan Yang · +8613845104003 · yangshanshan81@163.com
Always discuss trial participation with your own doctor first.
| Harbin, Heilongjiang, China, 150001 | Heilongjiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07540741